GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (OTCPK:NVLNF) » Definitions » Intrinsic Value: Projected FCF

Novelion Therapeutics (Novelion Therapeutics) Intrinsic Value: Projected FCF : $0.00 (As of May. 15, 2024)


View and export this data going back to 1988. Start your Free Trial

What is Novelion Therapeutics Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-15), Novelion Therapeutics's Intrinsic Value: Projected FCF is $0.00. The stock price of Novelion Therapeutics is $0.702. Therefore, Novelion Therapeutics's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Novelion Therapeutics's Intrinsic Value: Projected FCF or its related term are showing as below:

NVLNF's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.45
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Novelion Therapeutics Intrinsic Value: Projected FCF Historical Data

The historical data trend for Novelion Therapeutics's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novelion Therapeutics Intrinsic Value: Projected FCF Chart

Novelion Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.68 -4.95 -8.64 -14.44 -21.86

Novelion Therapeutics Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.83 -18.93 -20.56 -21.86 -22.28

Competitive Comparison of Novelion Therapeutics's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Novelion Therapeutics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novelion Therapeutics's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novelion Therapeutics's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Novelion Therapeutics's Price-to-Projected-FCF falls into.



Novelion Therapeutics Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Novelion Therapeutics's Free Cash Flow(6 year avg) = $-29.23.

Novelion Therapeutics's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Mar19)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-29.22688+-118.949/0.8)/19.022
=-22.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novelion Therapeutics  (OTCPK:NVLNF) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Novelion Therapeutics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.702/-22.444349892392
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novelion Therapeutics Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Novelion Therapeutics (Novelion Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3
Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.
Executives
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Stonepine Capital, L.p. 10 percent owner 919 NW BOND STREET, SUITE 204, BEND OR 97703
Michael Dennis Price officer: Chief Financial Officer
Benjamin Harshbarger officer: See Remarks ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
John J Orloff director C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Stephen L Sabba director DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
Mark Corrigan director
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Murray Stewart officer: Executive Vice President, R&D C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Mary T Szela director, officer: Chief Executive Officer 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121

Novelion Therapeutics (Novelion Therapeutics) Headlines

From GuruFocus

Novelion Therapeutics Observes World Lipodystrophy Day

By GlobeNewswire GlobeNewswire 03-31-2019

Novelion Therapeutics Announces Nasdaq Delisting

By Marketwired Marketwired 10-08-2019

Novelion Therapeutics Receives Delisting Notifications

By Marketwired Marketwired 07-05-2019

Novelion Therapeutics Announces Leadership Change

By Marketwired Marketwired 11-21-2018